Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TIPARP | Q7Z3E1 | 8/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23489990 | 1.00 | TRPC5 (0.47) | TRPC5POLBALDH1A1TIPARPKMT2A | |
| SCHEMBL23489993 | 1.00 | TRPC5 (0.47) | TRPC5POLBALDH1A1TIPARPKMT2A | |
| SCHEMBL23573308 | 0.95 | POLB (0.48) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL23490328 | 0.95 | POLB (0.48) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL23608268 | 0.93 | POLB (0.45) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL23489797 | 0.93 | POLB (0.45) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL23489891 | 0.92 | POLB (0.44) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL23608169 | 0.92 | POLB (0.44) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL23490378 | 0.92 | POLB (0.44) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL23608318 | 0.92 | POLB (0.45) | TRPC5POLBALDH1A1TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ADORA1, ADORA2A | TRPC5 517/4885POLB 2540/4885ALDH1A1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.